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506Unraveling the Pros and Cons
of Interferon-g Gene Regulation
Although transforming growth factor-b (TGF-b) inhibi-
tion of interferon-g (IFN-g) expression has been
known for some time, in this issue of Immunity, Yu
et al. (2006) are the first to detail the crosstalk between
proinflammatory cytokine and TGF-b signaling that
regulates IFN-g expression.
The regulation of interferon-g (IFN-g) gene expression is
a complex process because multiple signals converge
to control both mRNA expression and posttranscrip-
tional protein expression. Whereas many different cell
types have been reported to express IFN-g, the most
important sources for IFN-g are T cells (both CD4+ and
CD8+), NKT cells, and NK cells. Regulation of IFN-g ex-
pression in T cells has been the subject of investigation
by many labs, but its expression in NK cells has been
less widely studied, in large part due to the difficulty in
transfecting these cells or infecting them with retroviral
or lentiviral vectors. Induction of IFN-g expression in NK
cells occurs through many different types of stimula-
tion, including cross-linking of cell-surface receptors
and stimulation with cytokines, including interleukin-2
(IL-2), IL-12, and IL-18. Different regulatory regions of
the IFN-g locus have been identified and numerous
transcription factors have been implicated in the activa-
tion of IFN-g transcription, thus making the understand-
ing of how this gene is transcriptionally regulated com-
plex, as the model is constantly changing.
Inhibition of IFN-g gene expression has been less
widely studied. It has been known for some time that
TGF-b inhibits IFN-g expression by NK cells (Bellone
et al., 1995; Hunter et al., 1995; Ye et al., 1995). Further-
more, a major phenotype resulting from the develop-
ment of TGF-b-deficient mice was massive overexpres-
sion of IFN-g (Shull et al., 1992). However, until now, the
molecular mechanisms by which TGF-b inhibits IFN-g
expression have not been elucidated.
As deciphered by Yu et al. in this issue of Immunity
(Yu et al., 2006), there is an important balance between
the cytokines IL-12 and IL-18, and TGF-b in NK cells.
When NK cells are treated with both IL-12 and IL-18,
a tremendous synergy with respect to IFN-g gene ex-
pression is observed (Okamura et al., 1998). A molecular
basis for this synergy is that IL-12 treatment leads to the
activation of the STAT4 transcription factor, whichstrongly increased the recruitment of the IL-18-induced
transcription factor AP-1 to the IFN-g promoter (Naka-
hira et al., 2002). There is also reciprocal upregulation
of the receptors for both IL-12 and IL-18, thus making
the cells even more responsive to these stimuli. What
Yu et al. (2006) now show is that the IL-12 and IL-18
treatment also downregulates the ability of the NK cell
to respond to TGF-b (Figure 1). This process occurs
by both the downregulation of the mRNA and surface
expression of the TGF-b type II receptor (TGF-bRII) ex-
pression over time and the downregulation of SMAD2
mRNA. The SMAD family of transcription factors is crit-
ical for TGF-b signaling, so downregulation of these fac-
tors will decrease the cells’ ability to respond to TGF-b.
Additionally, SMAD3 protein, but not SMAD3 mRNA,
was also downregulated by the IL-12 and IL-18 treat-
ment. Of particular interest is the observation that the
overall downregulation of these signaling molecules
occurs under conditions of maximum IFN-g induction.
Although TGF-bRI and SMAD4 protein levels were not
affected, the inhibition of TGF-bRII and SMAD2 and
SMAD3 resulted in a decreased responsiveness to
TGF-b. Thus, as the cells are gearing up to maximally
produce IFN-g, their ability to respond to signals that
would dampen this response is weakened.
Next, theauthorsdirectlyexamined howTGF-b inhibits
IFN-gmRNA expression. They focused on two targets to
answer this question. The first target was T-bet, a gene
shown to be required for IFN-gexpression in CD4+ T cells
and NK cells (Szabo et al., 2002), and the second target
was the IFN-g gene itself (Figure 1). The authors clearly
demonstrate that there is a direct downregulation of
T-bet expression upon TGF-b treatment and that this
downregulation can be mediated through SMAD protein
interaction with the T-bet promoter (Figure 1). This effect
was maximized when SMAD3 and SMAD4 were used in
combination, whereas SMAD2 seemed to have little im-
pact on T-bet promoter activity. Interestingly, Yu et al.
(2006) could not overexpress SMAD4 in NK cells, and
although SMAD3 decreased T-bet in these cells, the ef-
fects were observed only in the presence of TGF-b, sug-
gesting that additional TGF-b-induced factors or protein
modifications (e.g., phosphorylation) are required. The
role of T-bet in IFN-g regulation has become controver-
sial, as a recent paper (Usui et al., 2006) showed that in
T cells, T-bet is not directly required for IFN-g expres-
sion. Instead T-bet was shown to inhibit GATA-3, a tran-
scription factor that inhibits IFN-g expression. However,
as shown in this manuscript, T-bet directly upregulates
activity of a truncated IFN-g promoter (2204), and
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507Figure 1. Schematic Representation of the
Differential Effects of IL-12, IL-18, and TGF-
b on Expression of IFN-g by NK Cells
IL-12 and IL-18 treatment downregulates the
ability of NK cells to respond to TGF-b
through downregulation of one chain of the
TGF-b receptor and the TGF-b-activated
transcription factors SMAD2 and SMAD3. In
contrast, TGF-b downregulates IFN-g ex-
pression though inhibition of the transcription
factor T-bet and direct interaction of the
SMAD proteins with the IFN-g promoter.cotransfection of the SMAD expression vectors directly
inhibit this T-bet-induced upregulation. Furthermore,
the authors demonstrate that SMAD3 directly interacts
with this region of the IFN-g promoter. Finally, Yu et al.
(2006) provide supporting evidence of their model by
demonstrating that NK cells from SMAD3-deficient mice
make 2-fold more IFN-g in response to IL-12 and IL-18
in vitro and in a generalized Shwartzman reaction. Thus,
the data presented in this study offer defined molecular
mechanisms by which NK cells, upon strong activation
as a result of cytokine stimulation, become less respon-
sive to TGF-b and how these same cells respond to the
antiinflammatory signals triggered by TGF-b.
So what further questions remain in regard to the
regulation of IFN-g expression in response to antiinflam-
matory signals such as TGF-b? It should be noted that
although TGF-b inhibits expression of IFN-g, the inhibi-
tion is not complete and is roughly only 50%–60% of
the cytokine-induced level. Thus, it is not clear how this
partial inhibition correlates with SMAD proteins binding
to the promoter. Is there a constant competition between
the SMAD proteins that inhibit transcription and tran-
scription factors that activate transcription (e.g., AP-1)?
Is there any role for GATA-3 in the inhibition of IFN-g
expression through interaction with the IFN-g promoter
in NK cells, as has been reported for T cells (Kaminuma
et al., 2004), and if so, is there any evidence for SMAD-
GATA3 interactions? Are other regions of the IFNG
genomic locus, which includes intronic, upstream, and
downstream enhancer elements, impacted by TGF-b
treatment? Are there chromatin conformation changes
(e.g., histone acetylation patterns) that occur as a result
of TGF-b treatment? Do the same mechanisms occur in T
cells, given the role of TGF-b in dampening the adaptive
immune response? While these and other questionsremain to be addressed, given the importance of IFN-g
in the host innate and adaptive immune response, it is
likely that analysis of the regulation of IFN-g gene ex-
pression will be a topic of interest for some time.
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